Pharvaris N.V.: insider trades · United States · SEC (Form 4)

About Pharvaris N.V.

Pharvaris N.V. is a United States-listed biopharmaceutical company trading on the Nasdaq under the ticker PHVS, with operational headquarters in Zug, Switzerland and U.S.-market reporting obligations through the SEC. For investors, the company fits the profile of a late-stage specialty biotech focused on bradykinin-mediated diseases, especially hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Its core scientific thesis is built around novel oral bradykinin B2 receptor antagonists designed to address unmet needs in a disease area where convenience, speed of relief, and attack prevention remain central commercial and clinical issues. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai)) Pharvaris was founded in the early 2020s and has since evolved into a clinical-stage company anchored by its lead asset, deucrictibant. The program includes both an immediate-release capsule and an extended-release tablet formulation. Positive phase 2 data in HAE supported advancement into pivotal development, with the company now evaluating deucrictibant in CHAPTER-3, a phase 3 study for the prevention of HAE attacks, and RAPIDe-3, a phase 3 study for on-demand treatment. In 2024, Pharvaris also expanded development plans into AAE-C1INH, broadening the potential commercial opportunity beyond classic hereditary disease. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai)) From a competitive standpoint, Pharvaris is trying to differentiate itself in a relatively concentrated HAE market through an oral mechanism and patient-friendly dosing profile. That matters because existing HAE therapies often compete on efficacy but can be limited by route of administration, convenience, or dosing burden. Pharvaris therefore appears positioned as a focused challenger rather than a broad platform biotech: the upside case depends heavily on clinical efficacy, safety, regulatory progress, and eventual market adoption if approval is achieved. The company has also used capital raises to support development, underscoring the cash-intensive nature of late-stage biotech execution. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai)) Geographically, Pharvaris is international in footprint: corporate presence in Switzerland, U.S. capital-markets access, and global clinical development activity. Recent highlights include full-year 2024 results, follow-on business updates in 2025 and 2026, and continued advancement of phase 3 studies. For market context, PHVS is therefore best viewed as a Nasdaq-listed United States company with an EU-based operational hub and a pipeline-driven equity story, highly sensitive to clinical readouts, regulatory milestones, and insider-transaction disclosures such as SEC Form 4 filings. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai))